Q-omics provides the consensus-scored TRAJ53 profile across patient tissues and cancer cell-line models. TRAJ53 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, TRAJ53 is differentially expressed in 6, with the highest sampling consensus in BRCA. Additionally, TRAJ53 RNA expression shows 7,898 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight BLCA, BRCA, and LSCC as cancer lineages where TRAJ53 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAJ53 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAJ53 survival associations across molecular data types. TRAJ53 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAJ53 RNA expression–survival associations across cancer types. High TRAJ53 expression shows unfavorable associations in BLCA, KICH, MESO, BRCA and ESCA, but favorable associations in SKCM. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .008). Together, the overview and detailed table identify BLCA as the clearest survival context for TRAJ53 RNA expression.
This table summarizes TRAJ53 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for TRAJ53. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAJ53 shows lower tumor expression in PAAD and higher tumor expression in BRCA, KIRC, STAD, COAD and THCA. The BRCA box plot shows higher TRAJ53 RNA expression in tumor versus normal tissue (log2 FC = +0.106, t-test p = .007).
This table shows molecular features associated with TRAJ53 in patient tissues and cancer cell lines. In patient samples, TRAJ53 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
